Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

By Ian Krop, Sung-Bae Kim, A. González-Martín, P. LoRusso, J. Ferrero, M. Smitt, R. Yu, A. Leung, H. Wildiers. The Lancet Oncology, 2014

652 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/256a0a98d55aaf207a97efa66f23dffafff9eb5a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Jorge Cardoso
2. Larry Norton
3. Ian Krop
4. C. Hudis

Citations in the corpus

• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, background): “treatment of physician's choice, in the TH3RESA trial) [101].”